Tamoxifen and Endometrial Cancer: From Experiment to Patient

  • V. J. Assikis
  • V. C. Jordan
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 140)

Abstract

Tamoxifen, a nonsteroidal antiestrogen, is the treatment of choice for adjuvant therapy in breast cancer patients. It is currently used both as a palliative treatment for advanced disease and as an adjunct following surgery for node positive or negative disease (Jordan 1994). In addition, tamoxifen’s estrogen-like properties have been noted to reduce the incidence of fatal myocardial infarction (McDonald and Stewart 1991; Stewart and Everington 1992) and maintain bone density in postmenopausal patients (Love et al. 1992; Ward et al. 1993; Kristensen et al. 1994). These observations led to the concept of testing tamoxifen as a preventive agent in women with a high risk for breast cancer. Clinical trials that will each recruit about 20000 women volunteers are now proceeding in the United States, the United Kingdom and Italy (Powles et al. 1994; Vanchieri 1992; Fisher and Redmond 1991). However, in contrast to the beneficial effect on bones and lipids, the estrogenic actions of tamoxifen in the uterus have raised serious doubts about the safety of long-term therapy. Satyaswaroop et al. (1984) first described the partial stimulation by tamoxifen of a human endometrial carcinoma transplanted in athymic mice. Gottardis et al. (1988) cotransplanted a human breast carcinoma and a human endometrial carcinoma into athymic mice to determine whether tamoxifen would control the estrogen stimulated growth of both tumors. Tamoxifen inhibited the growth of the breast tumor but encouraged the growth of the endometrial carcinoma.

Keywords

Placebo Obesity Estrogen Adenocarcinoma Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adami HO, Kruesmo UB, Bergkvist L, Person I, Pettersson B (1987) On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 55: 77–80PubMedCrossRefGoogle Scholar
  2. Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017PubMedCrossRefGoogle Scholar
  3. Assikis VJ, Jordan VC (1995) Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet 49: 241–257CrossRefGoogle Scholar
  4. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G (1990) Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378–380PubMedCrossRefGoogle Scholar
  5. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ (1994) Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55: 164–168PubMedCrossRefGoogle Scholar
  6. Cohen I, Altaras MM, Lew S, Tepper R, Beyth Y et al. (1994) Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol 55: 443–447PubMedCrossRefGoogle Scholar
  7. Dallenbach-Hellweg G, Hahn U (1995) Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 14: 7–15PubMedCrossRefGoogle Scholar
  8. Dauplat J, Le Bouedec G, Achard JL (1990) Adenocarcinome de l’ endométre chez 2 malades prenant du tamoxifene. Presse Med 19: 380–381PubMedGoogle Scholar
  9. De Muylder X, Neven P, De Somer M, Van Belle Y, Vanderick G et al. (1991) Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 36: 127–130CrossRefGoogle Scholar
  10. Early Breast Cancer Trialists Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24 000 deaths in 75 000 women. Lancet 339:1–15, 71–85Google Scholar
  11. Fisher B, Redmond C (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 83: 1278–1280PubMedCrossRefGoogle Scholar
  12. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–537PubMedCrossRefGoogle Scholar
  13. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T et al. (1989) Adjuvant tamoxifen in early breast cancer: occurence of new primary cancers. Lancet i:117–120CrossRefGoogle Scholar
  14. Fornander T, Hellstrom AC, Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850–1855PubMedCrossRefGoogle Scholar
  15. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC (1988) Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812–815PubMedGoogle Scholar
  16. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304–313PubMedCrossRefGoogle Scholar
  17. Horowitz RI, Feinstein AR (1986) Estrogens and endometrial cancer: response to arguments and current status of an epidemiologic controversy. Am J Med 81: 503–507CrossRefGoogle Scholar
  18. Jordan VC (ed) (1994) Long term tamoxifen treatment for breast cancer. University of Wisconsin Press, MadisonGoogle Scholar
  19. Kelsey JL, Whittemore AS (1994) Epidemiology and primary prevention of cancers of the breast, endometrium and ovary. A brief overview. Ann Epidemiol 4: 89–95Google Scholar
  20. Killackey MA, Hakes TB, Pierce VK (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69: 237–238PubMedGoogle Scholar
  21. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN et al. (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12: 992–997PubMedGoogle Scholar
  22. Lahti E, Vuopala S, Kauppila A, Blanco G, Ruokonen A et al. (1994) Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol 55: 410–414PubMedCrossRefGoogle Scholar
  23. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 326: 885–886Google Scholar
  24. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11: 485–490PubMedGoogle Scholar
  25. Malfetano J (1990) Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39:82–84PubMedCrossRefGoogle Scholar
  26. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ (1990) Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90: 207–208Google Scholar
  27. McDonald CC, Stewart HJ (1991) Fatal myocardial infarction in the Scottish tamoxifen trial Br Med J 303: 435–437Google Scholar
  28. Mignotte H, Sasco AJ, Lasset C, Saez S, Rivoire M et al. (1992) Traitement adjuvant du cancer du sein par tamoxifene et cancer de 1’ endomètre. Bull Cancer (Paris) 79: 969–977Google Scholar
  29. National Cancer Institute (1993) SEER cancer statistics review 1973–1990. NCI, Bethesda (Document no 93–2789 )Google Scholar
  30. Powles TJ,. Jones AL, Ashley SE, Obren MER, Tid Y et al. (1994) The Royal Mardsen Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31: 73–82PubMedCrossRefGoogle Scholar
  31. Satyaswaroop PG, Zaino RJ, Mortel R (1984) Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44: 4006–4010PubMedGoogle Scholar
  32. Segna RA, Dottino PR, Deligdisch L, Cohen CJ (1992) Tamoxifen and endometrial cancer. Mt Sinai J Med 59: 416–418PubMedGoogle Scholar
  33. Seoud MAF, Johnson J, Weed JC (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 82: 165–169PubMedGoogle Scholar
  34. Silva EG, Tornos CS, Follen-Mitchell M (1994) Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13: 248–258PubMedCrossRefGoogle Scholar
  35. Spinelli G, Bardazzi N, Citernesi A, Fontanarosa M, Curiel P (1991) Endometrial carcinoma in tamoxifen-treated breast cancer patients. J Chemother 3: 267–270PubMedGoogle Scholar
  36. Stewart HJ (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 11: 117–120PubMedGoogle Scholar
  37. Stewart HJ, Everington D (1992) Treatment of elderly patients with breast cancer(Letter). Br Med J 304:1569–1570CrossRefGoogle Scholar
  38. Stewart HJ, Knight GM (1989) Tamoxifen and the uterus and endometrium (Letter). Lancet 1: 375–376PubMedGoogle Scholar
  39. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrere CHF et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452PubMedCrossRefGoogle Scholar
  40. Vanchieri C (1992) Breast cancer study initiated in Italy. J Natl Cancer Inst 84: 1555–1556PubMedCrossRefGoogle Scholar
  41. Ward RL, Morgan G, Dailey D, Kelly PJ (1993) Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Bone Miner 22: 87–94Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • V. J. Assikis
    • 1
  • V. C. Jordan
    • 1
  1. 1.Robert H. Lurie Cancer CenterNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations